Skip to content

Mannkind MNKD Short-Term Investments

Short-Term Investments at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$132.57M+0.5%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$390.93M+24.1%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$278.14M+150%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$484.85M-40.4%
Cytokinetics logo
CytokineticsCYTK
$688.71M-20.3%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$278.49M+33.6%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's short-term investments?
Mannkind (MNKD) reported short-term investments of $81.03M in Q1 2026.
How has Mannkind's short-term investments changed year-over-year?
Mannkind's short-term investments decreased by 39.6% year-over-year, from $134.23M to $81.03M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.